New OpportunitiesThe company’s licensing of rights from Yale to an issued patent to use of simufilam as a potential treatment for seizures related to rare neurodevelopment disorders is seen as a positive development.

Bears Say

Clinical TrialsResults from the 76-week ReFocus-ALZ Phase 3 trial with simufilam in patients with mild-to-moderate Alzheimer’s disease did not meet the study’s pre-specified endpoints.

Financial RisksInvestment thesis risks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and potential need to raise additional funds under poor market conditions.

FLNA FAQ

What was Filana Therapeutics, Inc.’s price range in the past 12 months?

Filana Therapeutics, Inc. lowest stock price was $1.15 and its highest was $4.98 in the past 12 months.

What is Filana Therapeutics, Inc.’s market cap?

Filana Therapeutics, Inc.’s market cap is $96.13M.

When is Filana Therapeutics, Inc.’s upcoming earnings report date?

Filana Therapeutics, Inc.’s upcoming earnings report date is May 06, 2026 which is in 52 days.

How were Filana Therapeutics, Inc.’s earnings last quarter?

Filana Therapeutics, Inc. released its earnings results on Mar 12, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.3 by $0.04.

Is Filana Therapeutics, Inc. overvalued?

According to Wall Street analysts Filana Therapeutics, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Filana Therapeutics, Inc. pay dividends?

Filana Therapeutics, Inc. pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Filana Therapeutics, Inc. dividends here

What is Filana Therapeutics, Inc.’s EPS estimate?

Filana Therapeutics, Inc.’s EPS estimate is -0.23.

How many shares outstanding does Filana Therapeutics, Inc. have?

Filana Therapeutics, Inc. has 48,307,896 shares outstanding.

What happened to Filana Therapeutics, Inc.’s price movement after its last earnings report?

Filana Therapeutics, Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.3. Following the earnings report the stock price went down -6.699%.

Which hedge fund is a major shareholder of Filana Therapeutics, Inc.?

Currently, no hedge funds are holding shares in FLNA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Filana Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-97.94%

Trailing 12-Months

Asset Growth

-24.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Filana Therapeutics, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.